Trial Profile
Prospective observational study of Japanese melanoma patients treated with combination therapy using nivolumab and ipilimiumab
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 19 Sep 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Nivo/Ipi Combi-POS
- 13 Sep 2018 Status changed from not yet recruiting to discontinued.
- 04 Jun 2018 New trial record